Eric Zuckerman, DO

Eric Zuckerman, DO, has been the Board Chairman of the Pediatric IBD Foundation since it’s inception in 2008. Dr. Zuckerman is a Michigan based ophthalmologist whose daughter was diagnosed with Crohn’s Disease in 2003.

Dr. Zuckerman was selected to become an FDA patient representative in Pediatric IBD in 2012. Under Dr. Zuckerman’s leadership, the Foundation served as the lead co-sponsor of FDA’s Gastroenterology Regulatory Endpoints and Advancement of Therapeutics (GREAT 2) and GREAT 3 meetings. These groundbreaking meetings saw regulators, industry, and researchers at the same table in collaborative discussions about safety monitoring and streamlining drug approvals for children with inflammatory bowel disease. At GREAT 3, Dr. Zuckerman presented a model for a drug agnostic data sharing IBD registry to monitor drug safety called the Children’s REgistry for the Advancement of ThErapeutics, (CREATE). Continuing his work as an advocate for children with IBD, Dr. Zuckerman submitted testimony to Congress in support of a National Drug Safety registry for IBD. In addition to his work in the United States, Dr. Zuckerman has provided input on patient perspectives in drug development to the European Medicine Agencies. Through the Foundation’s web site and social media channels, Dr. Zuckerman regularly communicates with parents of children with IBD from all over the world. He frequently provides guidance to parents with educational information and resources, understanding from his own experience the challenges faced by families living with IBD.